Program
Granulocyte Colony-Stimulating Factor
Also written as “G-CSF plus plerixafor”, “G-CSF Plus Plerixafor” and “G-CSF”.
Its studies are mostly in Multiple Myeloma · Lymphoma, Non-Hodgkin · Sarcoma · Infertility, Female · Hot Flashes, led by 6 companies.
Drug pageGranulocyte Colony-Stimulating Factor: every studyMany companies study it; this page follows only the 16 they lead. All 179 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofiits history only | 110 open or running | phase 4since Oct 9, 2021 | Feb 11, 2005 | none ahead |
| Axaron Bioscienceits history only | 10 open or running | phase 2since Aug 18, 2005 | Aug 18, 2005 | none ahead |
| CSLits history only | 10 open or running | phase 1since May 31, 2019 | May 31, 2019 | none ahead |
| MenoGeniXits history only | 10 open or running | phase 1since Jul 30, 2018 | Jul 30, 2018 | none ahead |
| Newlife Fertility Centreits history only | 11 open or running | phase 4since Dec 8, 2023 | Dec 8, 2023 | none ahead |
| Terumoits history only | 10 open or running | no phasesince Sep 23, 2014 | Sep 23, 2014 | none ahead |
Also a collaborator on its studies: AnorMED.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Feb 11, 2005First studies: 2 phase 3 studiesNew to SanofiSanofi · NCT00103662, NCT00103610
- Aug 18, 2005Axaron Bioscience’s first study: phase 2 study in StrokeNew to Axaron BioscienceAxaron Bioscience · NCT00132470 · 42 enrolled · Germany
- May 4, 20063 phase 2 studies in Lymphoma, Non-HodgkinSanofi · NCT00322842, NCT00322491, NCT00322387
- Nov 2, 20064 phase 2 studiesSanofi · NCT00396331, NCT00396266, NCT00396201 and 1 more
- Mar 7, 2007Phase 2 study in Lymphoma, Non-HodgkinSanofi · NCT00444912 · 30 enrolled · United States
- Sep 23, 2014Terumo’s first study: no phase study in Healthy Apheresis DonorsNew to TerumoTerumo · NCT02253160 · 23 enrolled · United States
- Jul 30, 2018MenoGeniX’s first study: phase 1 study in Hot FlashesNew to MenoGeniXMenoGeniX · NCT03640754 · 61 enrolled · United States
- May 31, 2019CSL’s first study: phase 1 study in Hidradenitis SuppurativaNew to CSLCSL · NCT03972280 · 39 enrolled · Australia, Denmark, Germany
- Oct 9, 2021Phase 4 study in Autologous Haematopoietic Stem Cell TransplantSanofi · NCT05087212 · 53 enrolled · China
- Dec 8, 2023Newlife Fertility Centre’s first study: phase 4 study in InfertilityNew to Newlife Fertility CentreNewlife Fertility Centre · NCT06174298 · 300 planned · Canada
- Feb 29, 2024Named granulocyte colony-stimulating factorINNProposed as its International Nonproprietary Name in WHO's List 130
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06174298Infertility · Canada | 4 | Recruiting | Newlife Fertility Centre | Jan 10, 2025 | 300 |
| NCT05087212Autologous Haematopoietic Stem Cell Transplant · China | 4 | Completed | Sanofi | Dec 6, 2022 | 53 |
| NCT03972280Hidradenitis Suppurativa · Australia, Denmark, Germany | 1 | Completed | CSL | Oct 4, 2022 | 39 |
| NCT03640754Hot Flashes · United States | 1 | Completed | MenoGeniX | Jan 21, 2022 | 61 |
| NCT02253160Healthy Apheresis Donors · United States | – | Completed | Terumo | Jan 2015 | 23 |
| NCT00444912Lymphoma, Non-Hodgkin · United States | 2 | Completed | Sanofi | Jun 2009 | 30 |
| NCT00396331Multiple Myeloma · United States | 2 | Completed | Sanofi | Dec 2009 | 100 |
| NCT00396266Multiple Myeloma · Canada | 2 | Completed | Sanofi | Dec 2007 | 22 |
| NCT00396201Hodgkin Disease · United States | 2 | Completed | Sanofi | Oct 2006 | 22 |
| NCT00395967Multiple Myeloma · United States | 2 | Terminated | Sanofi | Jul 2005 | 5 |
| NCT00322842Lymphoma, Non-Hodgkin · Germany | 2 | Completed | Sanofi | Feb 2007 | 35 |
| NCT00322491Lymphoma, Non-Hodgkin · United States | 2 | Completed | Sanofi | Jun 2006 | 49 |
| NCT00322387Lymphoma, Non-Hodgkin · United States | 2 | Completed | Sanofi | Jul 2006 | 40 |
| NCT00132470Stroke · Germany | 2 | Completed | Axaron Bioscience | 42 | |
| NCT00103662Multiple Myeloma · United States, Canada, Germany | 3 | Completed | Sanofi | Oct 2006 | 302 |
| NCT00103610Lymphoma, Non-Hodgkin · United States, Canada | 3 | Completed | Sanofi | Jul 2006 | 298 |
How it is read
Names in the registry
- “G-CSF plus plerixafor”, 4 entries
- “G-CSF Plus Plerixafor”, 4 entries
- “G-CSF”, 3 entries
- “Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous”, 2 entries
- “Granulocyte colony-stimulating factor plus plerixafor”, 2 entries
Conditions, from the studies’ own filings
- Multiple Myeloma, 8 studies
- Lymphoma, Non-Hodgkin, 5 studies
- Sarcoma, 1 study
- Infertility, Female, 1 study
- Hot Flashes, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.